Roche-ImmunoGen's breast cancer drug Kadcyla wins EU nod

The European Commission has approved Roche and ImmunoGen's Kadcyla, or trastuzumab emtansine, as a treatment for HER-2 positive metastatic breast cancer. The approval was based on data from a late-stage trial that showed Kadcyla improved overall survival, compared with standard therapy. Based on the approval, Roche will pay ImmunoGen a $5 million milestone fee.

View Full Article in:

Medscape (free registration) · Wall Street Journal (tiered subscription model), The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX